Qihan Biotechnology scores $67m

Qihan Biotechnology Co, a Chinese provider of genome editing technology to cell therapies and organ transplantation, has raised $67 million in financing.

29 March 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles